Dihydrocubebin is primarily investigated for its anti-inflammatory and analgesic properties, making it a candidate for development in pain management and inflammatory conditions. It has shown inhibitory activity against enzymes involved in inflammation, such as phospholipase A2 and cyclooxygenase pathways. Due to its natural origin and structural similarity to lignans with known biological activity, it is also studied for potential antioxidant and antimicrobial effects. Research explores its use in pharmaceuticals, particularly in formulations aimed at reducing chronic inflammation and neuropathic pain. Additionally, it serves as a lead compound in the synthesis of derivatives to enhance bioavailability and therapeutic efficacy.